<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liontos, M.</style></author><author><style face="normal" font="default" size="100%">Anastasiou, I.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">DNA damage, tumor mutational load and their impact on immune responses against cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Translational Medicine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA damage</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutational load</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006217731&amp;doi=10.21037%2fatm.2016.07.11&amp;partnerID=40&amp;md5=86227c302227beb320bd1806c114bb15</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">4</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Advances in immunotherapy have changed the therapeutic landscape in many malignancies. Immune checkpoint inhibitors have already received regulatory approval in melanomas, lung, renal and bladder carcinomas. A common feature of these neoplasms is the increased mutational load, related to a possible increase number of tumor neoantigens that are recognized by the immune system. The mechanisms that DNA damage could confer to the mutational load and the formation of neoantigens and how this could be exploited to advance our immunotherapeutic strategies is discussed in this review. © Annals of Translational Medicine.</style></abstract><issue><style face="normal" font="default" size="100%">14</style></issue><notes><style face="normal" font="default" size="100%">Cited By :1Export Date: 21 February 2017</style></notes></record></records></xml>